ANGO
Price
$7.57
Change
-$0.13 (-1.69%)
Updated
Sep 20, 03:52 PM (EDT)
13 days until earnings call
HBIO
Price
$2.78
Change
-$0.00 (-0.00%)
Updated
Sep 19 closing price
46 days until earnings call
Ad is loading...

ANGO vs HBIO

Header iconANGO vs HBIO Comparison
Open Charts ANGO vs HBIOBanner chart's image
AngioDynamics
Price$7.57
Change-$0.13 (-1.69%)
Volume$200
CapitalizationN/A
Harvard Bioscience
Price$2.78
Change-$0.00 (-0.00%)
Volume$118.81K
CapitalizationN/A
View a ticker or compare two or three
ANGO vs HBIO Comparison Chart
Loading...
ANGO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
HBIO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ANGO vs. HBIO commentary
Sep 20, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANGO is a StrongBuy and HBIO is a Hold.

COMPARISON
Comparison
Sep 20, 2024
Stock price -- (ANGO: $7.60 vs. HBIO: $2.78)
Brand notoriety: ANGO and HBIO are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: ANGO: 53% vs. HBIO: 114%
Market capitalization -- ANGO: $233.95M vs. HBIO: $184.01M
ANGO [@Medical Specialties] is valued at $233.95M. HBIO’s [@Medical Specialties] market capitalization is $184.01M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANGO’s FA Score shows that 0 FA rating(s) are green whileHBIO’s FA Score has 1 green FA rating(s).

  • ANGO’s FA Score: 0 green, 5 red.
  • HBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, ANGO is a better buy in the long-term than HBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANGO’s TA Score shows that 3 TA indicator(s) are bullish while HBIO’s TA Score has 3 bullish TA indicator(s).

  • ANGO’s TA Score: 3 bullish, 3 bearish.
  • HBIO’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ANGO is a better buy in the short-term than HBIO.

Price Growth

ANGO (@Medical Specialties) experienced а +2.43% price change this week, while HBIO (@Medical Specialties) price change was -1.77% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.46%. For the same industry, the average monthly price growth was +0.65%, and the average quarterly price growth was -2.02%.

Reported Earning Dates

ANGO is expected to report earnings on Jan 02, 2025.

HBIO is expected to report earnings on Nov 05, 2024.

Industries' Descriptions

@Medical Specialties (+1.46% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ANGO($234M) has a higher market cap than HBIO($184M). ANGO YTD gains are higher at: -3.061 vs. HBIO (-48.037). HBIO has higher annual earnings (EBITDA): 8.03M vs. ANGO (-28.49M). ANGO has more cash in the bank: 60.9M vs. HBIO (4.28M). ANGO has less debt than HBIO: ANGO (4.73M) vs HBIO (42.8M). ANGO has higher revenues than HBIO: ANGO (330M) vs HBIO (112M).
ANGOHBIOANGO / HBIO
Capitalization234M184M127%
EBITDA-28.49M8.03M-355%
Gain YTD-3.061-48.0376%
P/E Ratio44.84N/A-
Revenue330M112M295%
Total Cash60.9M4.28M1,422%
Total Debt4.73M42.8M11%
FUNDAMENTALS RATINGS
ANGO vs HBIO: Fundamental Ratings
ANGO
HBIO
OUTLOOK RATING
1..100
138
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
99
Overvalued
PROFIT vs RISK RATING
1..100
10093
SMR RATING
1..100
9794
PRICE GROWTH RATING
1..100
4280
P/E GROWTH RATING
1..100
702
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ANGO's Valuation (66) in the Medical Specialties industry is somewhat better than the same rating for HBIO (99) in the Biotechnology industry. This means that ANGO’s stock grew somewhat faster than HBIO’s over the last 12 months.

HBIO's Profit vs Risk Rating (93) in the Biotechnology industry is in the same range as ANGO (100) in the Medical Specialties industry. This means that HBIO’s stock grew similarly to ANGO’s over the last 12 months.

HBIO's SMR Rating (94) in the Biotechnology industry is in the same range as ANGO (97) in the Medical Specialties industry. This means that HBIO’s stock grew similarly to ANGO’s over the last 12 months.

ANGO's Price Growth Rating (42) in the Medical Specialties industry is somewhat better than the same rating for HBIO (80) in the Biotechnology industry. This means that ANGO’s stock grew somewhat faster than HBIO’s over the last 12 months.

HBIO's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for ANGO (70) in the Medical Specialties industry. This means that HBIO’s stock grew significantly faster than ANGO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANGOHBIO
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
75%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 8 days ago
77%
Bullish Trend 4 days ago
75%
Declines
ODDS (%)
Bearish Trend 24 days ago
73%
Bearish Trend 9 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
71%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
ANGO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
HBIO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TSMEX15.710.01
+0.06%
Nuveen Quant Small/Mid Cap Eq A
RAGHX30.74N/A
N/A
Virtus KAR Health Sciences A
SSCYX6.68-0.01
-0.15%
Saratoga Small Capitalization A
OTFCX40.73-0.09
-0.22%
Invesco Capital Appreciation C
DTCAX18.78-0.08
-0.42%
BNY Mellon Sust US Equity A

ANGO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANGO has been loosely correlated with FLGT. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ANGO jumps, then FLGT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANGO
1D Price
Change %
ANGO100%
-0.52%
FLGT - ANGO
42%
Loosely correlated
+0.70%
KIDS - ANGO
42%
Loosely correlated
-3.28%
NVST - ANGO
41%
Loosely correlated
+0.95%
HBIO - ANGO
41%
Loosely correlated
-5.44%
CNMD - ANGO
39%
Loosely correlated
+1.62%
More

HBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, HBIO has been loosely correlated with FLGT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if HBIO jumps, then FLGT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HBIO
1D Price
Change %
HBIO100%
-5.44%
FLGT - HBIO
44%
Loosely correlated
+0.70%
AZTA - HBIO
42%
Loosely correlated
+0.51%
ICUI - HBIO
41%
Loosely correlated
-0.04%
KIDS - HBIO
41%
Loosely correlated
-3.28%
CTKB - HBIO
40%
Loosely correlated
-5.24%
More